HIV treatment as prevention: How scientific discovery occurred and translated rapidly into policy for the global response

Health Affairs

Volumn 31, Issue 7, 2012, Pages 1439-1449

  Cohen, Myron S ^a   Holmes, Charles ^b   Padian, Nancy ^b   Wolf, Megan ^b   Hirnschall, Gottfried ^c   Lo, Ying Ru ^d   Goosby, Eric ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b US Global AIDS   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d Health Organization's HIV Prevention Programme   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MALE HOMOSEXUAL; MEDICAL ETHICS; NONHUMAN; PATIENT COUNSELING; POST EXPOSURE PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; VIRUS TRANSMISSION;

ADVISORY COMMITTEES; ANTI-HIV AGENTS; CONDOMS; FEMALE; HEALTH POLICY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INTERNATIONAL COOPERATION; MALE; QUALITY OF HEALTH CARE; WORLD HEALTH ORGANIZATION;

EID: 84866275447     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2012.0250     Document Type: Article

References (67)

1. Joint United Nations Programme on HIV/AIDS. UNAIDS report on the global AIDS epidemic, 2010 [Internet]. Geneva: UNAIDS; 2010 [cited 2012 May 7]. Available from: http://www.unaids.org/globalreport/documents/20101123_Global-Report_full_en.pdf
2. Joint United Nations Programme on HIV/AIDS. UNAIDS World AIDS Day report: how to get to zero: faster. Smarter. Better [Internet]. Geneva: UNAIDS; 2011 [cited 2012 May 7]. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2216_WorldAIDSday_ report_2011_en.pdf
3. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet. 2008; 372(9639):669-84.
4. Royce RA, Sena A, Cates W, Cohen MS. Sexual transmission of HIV. N Engl J Med. 1997;336(15):1072-8.
5. Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8:553-63.
6. Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet. 2009;9(2):118-29.
7. Baeten JM, Kahle E, Lingappa JR, Coombs RW, Delaney-Moretlwe S, Nakku-Joloba E, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011;3(77):77ra29.
8. Atkins D, Best D, Briss BA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
9. Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention work. AIDS. 2010;24:621-35.
10. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV- infection in Thailand. N Engl J Med. 2009;361:2209-20.
11. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362:697-706.
12. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99.
13. Baeten J, Donnell D, Ndase P, Mugo N, Mujugira A, Celum C, et al. ARV PrEP for HIV-1 prevention among heterosexual men and women. Abstract presented at: Nineteenth Conference on Retroviruses and Opportunistic Infections, 2012 Mar 5-8, Seattle, WA. (Abstract No. 29).
14. Thigpen MC, Kebaabetswe PM, Smith DK, Segolodi TM, Soud FA, Chillag K, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. Abstract presented at: Sixth IAS Conference on HIV Pathogenesis, Treatment, and Prevention, 2011 Jul 18-20, Rome. (Abstract No. WELBC01).
15. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
16. Cohen MS, Muessig KE, Smith MK, Powers K, Kashuba AD. Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS. 2012 Apr 12. [Epub ahead of print].
17. To access the Appendix, click on the Appendix link in the box to the right of the article online
18. Siegfried N, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Cochrane Database Syst Rev. 2010;CD008272.
19. Cohen J. Breakthrough of the year: HIV treatment as prevention. Science. 2011;334(6063):1628.
20. Anglemyer A, Rutherford GW, Baggaley RC, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIVdiscordant couples. Cochrane Database Syst Rev. 2011 Aug 10;(8): CD009153.
21. Henry K, Chinnock BJ, Quinn RP, Fletcher CV, de Miranda P, Balfour HH Jr. Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. JAMA. 1988;259:3023-6.
22. Kashuba AD, Dyer JR, Kramer LM, Raasch RH, Eron JJ, Cohen MS. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1999; 43(8):1817-26.
23. Vernazza PL, Troiani L, Flepp MJ, Cone RW, Schock J, Roth F, et al. Potent antiretoviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS. 2000;14:117-21.
24. Cu-Uvin S, Caliendo A, Reinert S, Chang A, Juliano-Remollino C, Flanigan T, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS. 2000;14:415-21.
25. Quinn T, Wawer M, Sewankambo N. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342(13):921-9.
26. Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS. 2012;7(2):99-105.
27. Cohen MS, McCauley M, Sugarman J. Establishing HIV treatment as prevention in the HIV Prevention Trials Networks 052 randomized trial: an ethical odyssey. Clin Trials. 2012;9:340-7.
28. Smith K, Muessig KE, Powers KS, Miller WC, Cohen MS. ART and population level prevention of HIV: ecology, observation, and interpretation. PLOS Med. Forthcoming.
29. Sullivan P, Kayitenkore K, Chomba E, Karita E, Mwananyanda L, Vwalika C, et al. Reduction of HIV transmission risk while prescribed antiretroviral therapy (ARVT): misclassification of ARVT status as a methodological issue. AIDS Res Hum Retroviruses. 2010;26(10): A-1-184.
30. Castilla J, del Romero J, Hernando V, Marincovich B, García S, Rodríguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr. 2005;40(1):96-101.
31. Del Romero J, Castilla J, Hernando V, Rodriguez C, Garcia S. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ. 2010;340:c2205.
32. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092-8.
33. Bunnell R, Ekwaru JP, Solberg P, Wamai N, Bikaako-Kajura W, Were W, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS. 2006;20(1):85-92.
34. Hernando V, del Romero J, García S, Rodríguez C, del Amo J, Castilla J. Reducing sexual risk behavior among steady heterosexual serodiscordant couples in a testing and counseling program. Sex Transm Dis. 2009;36(10):621-8.
35. Melo MG, Santos BR, De Cassia Lira R, Varella IS, Turella ML, Rocha TM, et al. Sexual transmission of HIV-1 among serodiscordant couples in Porto Alegre, Southern Brazil. Sex Transm Dis. 2008;35(11):912-5.
36. Musicco M, Lazzarin A, Nicolosi A, Gasparini M, Costigliola P, Arici C, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med. 1994;154(17):1971-6.
37. Reynolds SJ, Makumbi F, Nakigozi G, Kagaayi J, Gray RH, Wawer M, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS. 2011; 25(4):473-7.
38. Wang L, Ge Z, Luo J, Shan D, Gao X, Ding G-W, et al. HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. J Acquir Immune Defic Syndr. 2010;55(2):232-8.
39. Tanser F, Bärnighausen T, Grapsa E, Newell M-L. Effect of ART coverage on rate of new HIV infections in a hyper-endemic, rural population: South Africa. Paper presented at: Nineteenth Conference on Retroviruses and Opportunistic Infections, 2012 Mar 5-8, Seattle, WA. (Paper No. 136LB).
40. Vernazza P, Hirschel B. Les personnes séropositives ne souffrant d'aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle. Schweiz Arzteztg. 2008;89:165-9.
41. Hasse B, Ledergerber B, Hirschel B, Vernazza P, Glass TR, Jeannin A, et al. Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV Cohort Study. Clin Infect Dis. 2010; 51(11):1314-22.
42. President's Emergency Plan for AIDS Relief [home page on the Internet]. Washington (DC): PEPFAR; [cited 2012 May 7]. Available from: http://www.pepfar.gov
43. President's Emergency Plan for AIDS Relief. PEPFAR Scientific Advisory Board [Internet]. Washington (DC): PEPFAR; [cited 2012 Jun 18]. Available from: http://www.pepfar.gov/sab/index.htm
44. World Health Organization [home page on the Internet]. Geneva:WHO; [cited 2012 May 7]. Available from: http://www.who.int/en/
45. World Health Organization. The strategic use of antiretrovirals for treatment and prevention of HIV infection. Report of a WHO technical consultation (14-16 November 2011) [Internet]. Geneva: WHO; 2011 [cited 2012 May 7]. Available from: http://www.who.int/hiv/pub/meetingreports/consultation_ 20111116/en/index.html
46. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin I, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med. 2011;8(11):e1001123.
47. El-Sadr WM, Coburn BJ, Blower S. Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. AIDS. 2011; 25(18):2295-9.
48. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents [Internet]. Washington (DC): HHS; [updated 2011 Oct 4; cited 2012 May 7]. Available from: http://www.aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatmentguidelines/0/
49. van Griensven F, van Wijngaarden JW, Barald S, Grulich A. The global epidemic of HIV infection among men who have sex with men. Curr Opin HIV AIDS. 2009;4:300-7.
50. World Health Organization. Prevention and treatment of HIV and other sexually transmitted infections among men who have sex with men and transgender people: recommendations for a public health approach [Internet]. Geneva: WHO; 2011 [cited 2012 Jun 12]. Available from: http://whqlibdoc.who.int/publications/2011/9789241501750_eng.pdf.
51. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363(3):257-65.
52. World Health Organization. 2010 ART guidelines for adults and adolescents: evidence map [Internet]. Geneva: WHO; c2012 [cited 2012 May 7]. Available from: http://www.who.int/hiv/topics/treatment/evidence/en/index.html
53. Gardner EM, McLees MP, Steiner JF. The spectrum of engagement in HIV care and its relevance to test-andtreat strategies for prevention of HIV infection. Clin Infect Dis. 2011; 52(6):793-800.
54. Burns DN, Dieffenbach CW, Vermund SH. Rethinking prevention of HIV type 1 infection. Clin Infect Dis. 2010;51(6):725-31.
55. Brinkhof MWG, Egger M, Boulle A, Weigel R, Messou E, Mathers C, et al. Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med. 2009;6(4):e1000066.
56. Centers for Disease Control and Prevention. Vital signs: HIV prevention through care and treatment- United States. MMWR Morb Mortal Wkly Rep [serial on the Internet]. 2011 Dec 2;60(47):1618-23 [cited 2012 Jun 12]. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6047a4.htm?s_cid=mm6047a4_w
57. HIV Prevention Trials Network. TLCplus: a study to evaluate the feasibility of an enhanced test, link to care, plus treat approach for HIV prevention in the United States [Internet]. Durham (NC): FHI360; [cited 2012 May 7]. Available from: http://www.hptn.org/research_studies/hptn065.asp
58. World Health Organization. Guidance on couples HIV testing and counselling, including antiretroviral therapy for treatment and prevention in serodiscordant couples: recommendations for a public health approach [Internet]. Geneva: WHO; 2012 Apr [cited 2012 Jun 12]. Available from: http://whqlibdoc.who.int/publications/2012/9789241501972_eng.pdf
59. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access: recommendations for a public health approach [Internet]. Geneva: WHO; [cited 2012 Jun 12]. Available from: http://www.who.int/hiv/pub/mtct/pmtct/en/
60. World Health Organization. Programmatic update: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants [Internet]. Geneva: WHO; 2012 Apr [cited 2012 May 7]. Available from: http://www.who.int/hiv/pub/mtct/programmatic_update2012/en/index.html
61. ClinicalTrials.gov. Strategic Timing of Antiretroviral Treatment (START). [Internet]. Bethesda (MD): NIH; c2012 [last updated 2012 Jun 7; cited 2012 Jun 22]. Available from: http://clinicaltrials.gov/ct2/show/NCT00867048
62. Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS ONE. 2012; 7(2):e30216.
63. Russell S. City endorses new policy for treatment of HIV. New York Times. 2010 April 3.
64. Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, Vitoria M, et al. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res. 2011;9:446-69.
65. Boily M, Padian N, Alsallaq R, Eaton J, Hallett T. Three new community level trials of HIV prevention. PLoS Medicine. Forthcoming.
66. Clinton H. Creating an AIDS-free generation [Internet]. Washington (DC): Department of State; 2011 Nov 8 [cited 2012 Jun 5]. Available from: http://www.state.gov/secretary/rm/2011/11/176810.htm
67. Obama B. Remarks by the president on World AIDS Day, George Washington University, Washington D.C.; December 1, 2011 [Internet]. Washington (DC): White House; 2011 Dec 1 [cited 2012 Jun 12]. Available from: http://www.whitehouse.gov/photos-and-video/video/2011/12/01/president-obamaworld-aids-day#transcript